2017
Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors
Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, Gydush G, Reed SC, Rotem D, Rhoades J, Loginov D, Livitz D, Rosebrock D, Leshchiner I, Kim J, Stewart C, Rosenberg M, Francis JM, Zhang CZ, Cohen O, Oh C, Ding H, Polak P, Lloyd M, Mahmud S, Helvie K, Merrill MS, Santiago RA, O’Connor E, Jeong SH, Leeson R, Barry RM, Kramkowski JF, Zhang Z, Polacek L, Lohr JG, Schleicher M, Lipscomb E, Saltzman A, Oliver NM, Marini L, Waks AG, Harshman LC, Tolaney SM, Van Allen EM, Winer EP, Lin NU, Nakabayashi M, Taplin ME, Johannessen CM, Garraway LA, Golub TR, Boehm JS, Wagle N, Getz G, Love JC, Meyerson M. Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors. Nature Communications 2017, 8: 1324. PMID: 29109393, PMCID: PMC5673918, DOI: 10.1038/s41467-017-00965-y.Peer-Reviewed Original ResearchConceptsWhole-exome sequencingCell-free DNATumor biopsiesTumor whole-exome sequencingTumor contentHigh concordanceClonal somatic mutationsMetastatic tumorsBreast cancerMetastatic prostateBlood samplesPatientsTumor mutationsCfDNA profilingBiopsyMutational signaturesSomatic mutationsTumorsNumber alterationsConcordanceComprehensive profilingNeoantigensSequencingProstateCancer
2000
A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma
Dawson N, Conaway M, Halabi S, Winer E, Small E, Lake D, Vogelzang N. A randomized study comparing standard versus moderately high dose megestrol acetate for patients with advanced prostate carcinoma. Cancer 2000, 88: 825-834. PMID: 10679652, DOI: 10.1002/(sici)1097-0142(20000215)88:4<825::aid-cncr13>3.0.co;2-n.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate carcinomaMegestrol acetateProstate carcinomaStable diseasePartial responsePerformance statusDay doseHigh-dose megestrol acetateEnd pointPossible dose-response effectDose megestrol acetateHigher baseline PSAOral megestrol acetateHigh-dose therapyPoor performance statusPrimary end pointSecondary end pointsMedian survival timeAdvanced prostate carcinomaDose-response effectDose-response correlationEvaluable diseaseMeasurable diseaseDose therapyBaseline PSA
1999
Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study.
Kantoff P, Halabi S, Conaway M, Picus J, Kirshner J, Hars V, Trump D, Winer E, Vogelzang N. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. Journal Of Clinical Oncology 1999, 17: 2506-13. PMID: 10561316, DOI: 10.1200/jco.1999.17.8.2506.Peer-Reviewed Original ResearchConceptsHormone-refractory prostate cancerTreatment failureDisease progressionPain controlSurvival durationProstate cancerResults of treatmentOverall survivalPalliative optionMore frequent responsesPatientsHydrocortisoneLife parametersNew drugsCancerMitoxantroneProgressionSurvivalDiseasePossible benefitsMenTreatmentFrequent responseFailureDuration